Literature DB >> 23616863

Electronic medical record prompts for lab orders in patients initiating statins.

D G Carroll, C Alexander, E A Radford, J Leeper, D N Carroll.   

Abstract

BACKGROUND: The Institute of Medicine (IOM) reports that at least a fourth of all medication related injuries are preventable. Therefore, the IOM recommends healthcare organizations and providers implement electronic prescribing and clinical decision support systems in practices to aid in medication error prevention.
OBJECTIVE: To assess the impact of noninstrusive-intrusive prompts from an electronic medical record on recommended baseline and follow up laboratory monitoring, CK and liver transaminase levels (AST and ALT), in patients initiated on statin therapy.
METHODS: Hybrid nonintrusive-intrusive prompts for laboratory monitoring specific for statin initiation were implemented in the electronic medical record system in a community based, university affiliated family medicine residency program. A retrospective chart review was conducted to compare and assess laboratory monitoring in patients initiated on statin therapy from two specific time periods: a six month period prior to initiation of the prompts and a six month period after initiation of the prompts.
RESULTS: One hundred seventy three patients met inclusion criteria. There were no significant differences in assessment of baseline liver transaminases and CK levels from the initial study period to the follow up study period. There were significant differences in follow up liver transaminase levels (18% vs 33%, p = 0.035) and CK levels (none vs 7%, p = 0.03) from the initial study period to the activated prompt interval.
CONCLUSION: A hybrid nonintrusive-intrusive specific prompts for laboratory monitoring triggered by statin initiation within an electronic medical record improved follow up lab assessments for liver transaminases and CK but did not improve baseline assessments of CK or liver transaminases.

Entities:  

Keywords:  Computerized medical records; HMG-COA; ambulatory care facilities; clinical laboratory techniques; statins

Year:  2011        PMID: 23616863      PMCID: PMC3631910          DOI: 10.4338/ACI-2010-07-RA-0044

Source DB:  PubMed          Journal:  Appl Clin Inform        ISSN: 1869-0327            Impact factor:   2.342


  25 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

3.  The extent and importance of unintended consequences related to computerized provider order entry.

Authors:  Joan S Ash; Dean F Sittig; Eric G Poon; Kenneth Guappone; Emily Campbell; Richard H Dykstra
Journal:  J Am Med Inform Assoc       Date:  2007-04-25       Impact factor: 4.497

Review 4.  Prompts to encourage appointment attendance for people with serious mental illness.

Authors:  S Reda; S Makhoul
Journal:  Cochrane Database Syst Rev       Date:  2001

5.  First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization.

Authors:  J V Selby; B Ettinger; B E Swain; J B Brown
Journal:  Diabetes Care       Date:  1999-01       Impact factor: 19.112

6.  Use and monitoring of "statin" lipid-lowering drugs compared with guidelines.

Authors:  S A Abookire; A S Karson; J Fiskio; D W Bates
Journal:  Arch Intern Med       Date:  2001-01-08

7.  Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy.

Authors:  Amy T Calabrese; Kim C Coley; Stacey V DaPos; Dennis Swanson; R Harsha Rao
Journal:  Arch Intern Med       Date:  2002-02-25

8.  Improved therapeutic monitoring with several interventions: a randomized trial.

Authors:  Adrianne C Feldstein; David H Smith; Nancy Perrin; Xiuhai Yang; Mary Rix; Marsha A Raebel; David J Magid; Steven R Simon; Stephen B Soumerai
Journal:  Arch Intern Med       Date:  2006-09-25

9.  Appropriateness of antiepileptic drug level monitoring.

Authors:  R A Schoenenberger; M J Tanasijevic; A Jha; D W Bates
Journal:  JAMA       Date:  1995 Nov 22-29       Impact factor: 56.272

10.  Improving fecal occult blood testing compliance using a mailed educational reminder.

Authors:  Jeffrey K Lee; Veronica Reis; Shanglei Liu; Lorraine Conn; Erik J Groessl; Theodore G Ganiats; Samuel B Ho
Journal:  J Gen Intern Med       Date:  2009-09-23       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.